ArticleComputational and structural biotechnology journal2026
MSICKB: A Curated Knowledgebase for Exploring Molecular Heterogeneity and Biomarker Prioritization in Microsatellite Instability Cancers.
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Benchmarking Large Language Models and Prompt Engineering Strategies in Microsatellite Instability Cancers: Evaluation Study.Journal of medical Internet research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microsatellite instability (MSI) is a clinically actionable molecular phenotype in cancer, but MSI-associated findings remain fragmented across tumor types, study designs, and biomarker categories, limiting systematic cross-cancer comparison and evidence-guided biomarker prioritization. To address this problem, we developed the Microsatellite Instability Cancer Knowledgebase (MSICKB), a manually curated and literature-traceable resource for MSI-associated molecular and clinical features. We collected and curated 1,382 MSI-related features from 492 publications covering 31 cancer types and organized the evidence into 4 major dimensions: genetic and molecular alterations, clinicopathological features, prognostic factors, and therapeutic response. Based on curated gene-cancer associations, we constructed a simple bipartite network to examine the cross-cancer organization of MSI-associated genes. In the primary network, 99 genes were linked to 13 cancer types through 147 unique gene-cancer edges. Gene degree was strongly right-skewed, with most genes linked to a single cancer type and a small subset showing broader cross-cancer connectivity. Using an operational cutoff of degree ≥ 3, we identified 9 hub genes: BRAF, CD274, KRAS, MLH1, MSH2, PTEN, RNF43, TGFBR2, and TP53. These hubs were enriched in canonical MSI-related pathways, including mismatch repair, cancer signaling, and immune regulation. To provide external molecular support, we further evaluated the hub genes in 3 The Cancer Genome Atlas cohorts with established MSI relevance. In pooled analyses of 336 MSI-high and 1,214 non-MSI-high tumors, all 9 hub genes showed significant differences in mutation prevalence and expression. Overall, MSICKB provides a structured framework for MSI-related evidence synthesis, cross-cancer comparison, and biomarker prioritization and is freely available at http://www.sysbio.org.cn/MSICKB/.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.